Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyAminophylline
Identification
- Name
- Aminophylline
- Accession Number
- DB01223 (APRD00329)
- Type
- Small Molecule
- Groups
- Approved
- Description
Aminophylline is a drug combination that contains theophylline and ethylenediamine in a 2:1 ratio. Once in the body, theophylline is released and acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Similar to other theophyllines, aminophylline is indicated for the treatment of lung diseases such as asthma, chronic bronchitis, and COPD. The majority of aminophylline medications are discontinued and the remaining medications on the market are in short supply.
- Structure
Structure for DB01223 (Aminophylline)
- Synonyms
- Aminophyllin
- Somophyllin
- Theophylline ethylenediamine
- Product Ingredients
Ingredient UNII CAS InChI Key Aminophylline dihydrate C229N9DX94 5897-66-5 FXNJPZOEDHBGEY-UHFFFAOYSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Aminophylline Inj 25mg/ml Solution 25 mg Intravenous Omega Laboratories Ltd 1984-12-31 Not applicable Canada 
Aminophylline Inj 50mg/ml Solution 50 mg Intravenous Omega Laboratories Ltd 1984-12-31 Not applicable Canada Aminophylline Injection 50mg/ml Solution 50 mg Intravenous Hospira, Inc. 1981-12-31 2012-08-03 Canada Aminophylline Injection USP Solution 25 mg Intravenous Pfizer 1981-12-31 Not applicable Canada Aminophylline Tab 0.1gm Tablet 100 mg Oral Lederle Cyanamid Canada Inc. 1951-12-31 2000-08-02 Canada Aminophylline Tab 100mg Tablet 97.5 mg Oral Stanley Pharmaceuticals, A Division Of Vita Health Products Inc. 1957-12-31 2002-07-31 Canada Jaa Aminophylline Tab 100mg Tablet 100 mg Oral Jaapharm Canada Inc. 1993-12-31 2016-08-10 Canada Phyllocontin Tablet, extended release 225 mg Oral Purdue Pharma 1993-12-31 2011-08-04 Canada Phyllocontin-350 Tablet, extended release 350 mg Oral Purdue Pharma 1993-12-31 2011-08-04 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Aminophylline Injection, solution 25 mg/mL Intravenous Cardinal Health 2011-02-11 Not applicable US 
Aminophylline Injection, solution 25 mg/mL Intravenous Hospira, Inc. 1983-10-26 2018-02-20 US Aminophylline Tablet 200 mg/1 Oral West Ward Pharmaceutical 1976-05-28 2017-11-02 US Aminophylline Injection, solution 25 mg/mL Intravenous General Injectables & Vaccines 2010-07-01 Not applicable US Aminophylline Injection, solution 25 mg/mL Intravenous Medical Purchasing Solutions, Llc 2005-05-10 Not applicable US Aminophylline Injection, solution 25 mg/mL Intravenous Hospira, Inc. 1983-10-26 Not applicable US Aminophylline Tablet 100 mg/1 Oral West Ward Pharmaceutical 1975-11-26 2017-11-02 US Aminophylline Injection, solution 25 mg/mL Intravenous Cardinal Health 2011-02-11 Not applicable US Aminophylline Injection, solution 25 mg/mL Intravenous Hospira, Inc. 1983-10-26 2018-02-20 US Aminophylline Injection, solution 25 mg/mL Intravenous Hospira, Inc. 1983-10-26 Not applicable US - International/Other Brands
- Minomal / Somophyllin / Truphylline
- Categories
- Alkaloids
- Amines
- Anti-Asthmatic Agents
- Autonomic Agents
- Bronchodilator Agents
- Cardiotonic Agents
- Cardiovascular Agents
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors (weak)
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 CYP2E1 Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Diamines
- Drugs for Obstructive Airway Diseases
- Enzyme Inhibitors
- Ethylenediamines
- Methylxanthine
- Neurotransmitter Agents
- Peripheral Nervous System Agents
- Pharmaceutical Preparations
- Phosphodiesterase Inhibitors
- Polyamines
- Protective Agents
- Purinergic Agents
- Purinergic Antagonists
- Purinergic P1 Receptor Antagonists
- Purines
- Purinones
- Respiratory Smooth Muscle Relaxants
- Respiratory System Agents
- Theophylline
- Theophylline Derivatives
- Xanthines
- UNII
- 27Y3KJK423
- CAS number
- 317-34-0
- Weight
- Average: 420.4264
Monoisotopic: 420.198199306 - Chemical Formula
- C16H24N10O4
- InChI Key
- FQPFAHBPWDRTLU-UHFFFAOYSA-N
- InChI
- InChI=1S/2C7H8N4O2.C2H8N2/c2*1-10-5-4(8-3-9-5)6(12)11(2)7(10)13;3-1-2-4/h2*3H,1-2H3,(H,8,9);1-4H2
- IUPAC Name
- bis(1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione); ethane-1,2-diamine
- SMILES
- NCCN.CN1C2=C(NC=N2)C(=O)N(C)C1=O.CN1C2=C(NC=N2)C(=O)N(C)C1=O
Pharmacology
- Indication
For the treatment of bronchospasm due to asthma, emphysema and chronic bronchitis.
- Structured Indications
- Pharmacodynamics
Aminophylline is the ethylenediamine salt of theophylline. Theophylline stimulates the CNS, skeletal muscles, and cardiac muscle. It relaxes certain smooth muscles in the bronchi, produces diuresis, and causes an increase in gastric secretion.
- Mechanism of action
Aminophylline is the ethylenediamine salt of theophylline. After ingestion, theophylline is released from aminophylline, and theophylline relaxes the smooth muscle of the bronchial airways and pulmonary blood vessels and reduces airway responsiveness to histamine, methacholine, adenosine, and allergen. Theophylline competitively inhibits type III and type IV phosphodiesterase (PDE), the enzyme responsible for breaking down cyclic AMP in smooth muscle cells, possibly resulting in bronchodilation. Theophylline also binds to the adenosine A2B receptor and blocks adenosine mediated bronchoconstriction. In inflammatory states, theophylline activates histone deacetylase to prevent transcription of inflammatory genes that require the acetylation of histones for transcription to begin.
Target Actions Organism AcGMP-inhibited 3',5'-cyclic phosphodiesterase A inhibitorHuman AAdenosine receptor A1 antagonistHuman AAdenosine receptor A3 antagonistHuman AHistone deacetylase 2 activatorHuman - Absorption
- Not Available
- Volume of distribution
- 0.3 to 0.7 L/kg
- Protein binding
60%
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
7-9 hours
- Clearance
- 0.29 mL/kg/min [postnatal age 3-15 days]
- 0.64 mL/kg/min [postnatal age 25-57 days]
- 1.7 mL/kg/min [ 1-4 years]
- 1.6 mL/kg/min [4-12 years]
- 0.9 mL/kg/min [13-15 years]
- 1.4 mL/kg/min [16-17 years]
- 0.65 mL/kg/min [Adults (16-60 years), non-smoking asthmatics]
- 0.41 mL/kg/min [Elderly (>60 years). liver, and renal function]
- 0.33 mL/kg/min [Acute pulmonary edema]
- 0.54 mL/kg/min [COPD->60 years, stable non-smoker >1 year]
- 0.48 mL/kg/min [COPD with cor pulmonale]
- 1.25 mL/kg/min [Cystic fibrosis (14-28 years)]
- 0.31 mL/kg/min [Liver disease -cholestasis]
- 0.35 mL/kg/min [cirrhosis]
- 0.65 mL/kg/min [acute hepatitis]
- 0.47 mL/kg/min [Sepsis with multi-organ failure]
- 0.38 mL/kg/min [hypothyroid]
- 0.8 mL/kg/min [hyperthyroid]
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group 1,10-Phenanthroline The serum concentration of Aminophylline can be decreased when it is combined with 1,10-Phenanthroline. Experimental 3,4-Dichloroisocoumarin The serum concentration of Aminophylline can be decreased when it is combined with 3,4-Dichloroisocoumarin. Experimental 4-(2-Aminoethyl)Benzenesulfonyl Fluoride The serum concentration of Aminophylline can be decreased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride. Experimental Abiraterone The serum concentration of Aminophylline can be increased when it is combined with Abiraterone. Approved Acebutolol Acebutolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Adalimumab The serum concentration of Aminophylline can be decreased when it is combined with Adalimumab. Approved Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Aminophylline. Approved, Investigational Albinterferon Alfa-2B The metabolism of Aminophylline can be decreased when combined with Albinterferon Alfa-2B. Investigational Allopurinol The serum concentration of Aminophylline can be increased when it is combined with Allopurinol. Approved Alogliptin The serum concentration of Aminophylline can be decreased when it is combined with Alogliptin. Approved Alpha-1-proteinase inhibitor The serum concentration of Aminophylline can be decreased when it is combined with Alpha-1-proteinase inhibitor. Approved Alprazolam The therapeutic efficacy of Alprazolam can be decreased when used in combination with Aminophylline. Approved, Illicit, Investigational Alprenolol Alprenolol may decrease the bronchodilatory activities of Aminophylline. Approved, Withdrawn Amiodarone The metabolism of Aminophylline can be decreased when combined with Amiodarone. Approved, Investigational Amobarbital The serum concentration of Aminophylline can be decreased when it is combined with Amobarbital. Approved, Illicit Amprenavir The serum concentration of Aminophylline can be decreased when it is combined with Amprenavir. Approved, Investigational Antithrombin III human The serum concentration of Aminophylline can be decreased when it is combined with Antithrombin III human. Approved Apalutamide The serum concentration of Aminophylline can be decreased when it is combined with Apalutamide. Approved, Investigational Apixaban The serum concentration of Aminophylline can be decreased when it is combined with Apixaban. Approved Aprepitant The serum concentration of Aminophylline can be increased when it is combined with Aprepitant. Approved, Investigational Aprotinin The serum concentration of Aminophylline can be decreased when it is combined with Aprotinin. Approved, Investigational, Withdrawn Argatroban The serum concentration of Aminophylline can be decreased when it is combined with Argatroban. Approved, Investigational Asunaprevir The serum concentration of Aminophylline can be decreased when it is combined with Asunaprevir. Approved, Investigational, Withdrawn Atazanavir The metabolism of Aminophylline can be decreased when combined with Atazanavir. Approved, Investigational Atenolol Atenolol may decrease the bronchodilatory activities of Aminophylline. Approved Atomoxetine The metabolism of Aminophylline can be decreased when combined with Atomoxetine. Approved Azithromycin The metabolism of Aminophylline can be decreased when combined with Azithromycin. Approved Barbexaclone The serum concentration of Aminophylline can be decreased when it is combined with Barbexaclone. Experimental Barbital The serum concentration of Aminophylline can be decreased when it is combined with Barbital. Illicit Batimastat The serum concentration of Aminophylline can be decreased when it is combined with Batimastat. Experimental Benazepril The serum concentration of Aminophylline can be decreased when it is combined with Benazepril. Approved, Investigational Benzamidine The serum concentration of Aminophylline can be decreased when it is combined with Benzamidine. Experimental Betaxolol Betaxolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Bisoprolol Bisoprolol may decrease the bronchodilatory activities of Aminophylline. Approved Bivalirudin The serum concentration of Aminophylline can be decreased when it is combined with Bivalirudin. Approved, Investigational BMS-906024 The therapeutic efficacy of BMS-906024 can be decreased when used in combination with Aminophylline. Investigational Boceprevir The metabolism of Aminophylline can be decreased when combined with Boceprevir. Approved, Withdrawn Bopindolol Bopindolol may decrease the bronchodilatory activities of Aminophylline. Approved Bortezomib The metabolism of Aminophylline can be decreased when combined with Bortezomib. Approved, Investigational Bosentan The serum concentration of Aminophylline can be decreased when it is combined with Bosentan. Approved, Investigational Bromazepam The therapeutic efficacy of Bromazepam can be decreased when used in combination with Aminophylline. Approved, Illicit, Investigational Bupranolol Bupranolol may decrease the bronchodilatory activities of Aminophylline. Approved Caffeine The metabolism of Aminophylline can be decreased when combined with Caffeine. Approved Camazepam The therapeutic efficacy of Camazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Camostat The serum concentration of Aminophylline can be decreased when it is combined with Camostat. Experimental Candoxatril The serum concentration of Aminophylline can be decreased when it is combined with Candoxatril. Experimental Candoxatrilat The serum concentration of Aminophylline can be decreased when it is combined with Candoxatrilat. Experimental Captopril The serum concentration of Aminophylline can be decreased when it is combined with Captopril. Approved Carbamazepine The serum concentration of Aminophylline can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbimazole The serum concentration of Aminophylline can be increased when it is combined with Carbimazole. Approved, Investigational Carbomycin The metabolism of Aminophylline can be decreased when combined with Carbomycin. Vet Approved Carteolol Carteolol may decrease the bronchodilatory activities of Aminophylline. Approved CE-326597 The therapeutic efficacy of CE-326597 can be decreased when used in combination with Aminophylline. Investigational Celiprolol Celiprolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Cepeginterferon alfa-2B The metabolism of Aminophylline can be decreased when combined with Cepeginterferon alfa-2B. Investigational Ceritinib The serum concentration of Aminophylline can be increased when it is combined with Ceritinib. Approved Chlordiazepoxide The therapeutic efficacy of Chlordiazepoxide can be decreased when used in combination with Aminophylline. Approved, Illicit, Investigational Chlorotrianisene The serum concentration of Aminophylline can be increased when it is combined with Chlorotrianisene. Investigational, Withdrawn Cholesterol The serum concentration of Aminophylline can be decreased when it is combined with Cholesterol. Approved, Experimental, Investigational Chymostatin The serum concentration of Aminophylline can be decreased when it is combined with Chymostatin. Experimental Cilastatin The serum concentration of Aminophylline can be decreased when it is combined with Cilastatin. Approved, Investigational Cilazapril The serum concentration of Aminophylline can be decreased when it is combined with Cilazapril. Approved Cimetidine The metabolism of Aminophylline can be decreased when combined with Cimetidine. Approved, Investigational Cinoxacin The metabolism of Aminophylline can be decreased when combined with Cinoxacin. Approved, Investigational, Withdrawn Citalopram The metabolism of Aminophylline can be decreased when combined with Citalopram. Approved Clarithromycin The metabolism of Aminophylline can be decreased when combined with Clarithromycin. Approved Clemastine The metabolism of Aminophylline can be decreased when combined with Clemastine. Approved, Investigational Clobazam The therapeutic efficacy of Clobazam can be decreased when used in combination with Aminophylline. Approved, Illicit Clonazepam The therapeutic efficacy of Clonazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Cloranolol Cloranolol may decrease the bronchodilatory activities of Aminophylline. Experimental Clorazepate The therapeutic efficacy of Clorazepate can be decreased when used in combination with Aminophylline. Approved, Illicit Clotrimazole The metabolism of Aminophylline can be decreased when combined with Clotrimazole. Approved, Vet Approved Cobicistat The metabolism of Aminophylline can be decreased when combined with Cobicistat. Approved Conivaptan The serum concentration of Conivaptan can be increased when it is combined with Aminophylline. Approved, Investigational Conjugated estrogens The serum concentration of Aminophylline can be increased when it is combined with Conjugated estrogens. Approved Crizotinib The metabolism of Aminophylline can be decreased when combined with Crizotinib. Approved Cyclosporine The metabolism of Aminophylline can be decreased when combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproterone acetate The serum concentration of Aminophylline can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Dabigatran etexilate The serum concentration of Aminophylline can be decreased when it is combined with Dabigatran etexilate. Approved Dabrafenib The serum concentration of Aminophylline can be decreased when it is combined with Dabrafenib. Approved, Investigational Daidzein The serum concentration of Aminophylline can be increased when it is combined with Daidzein. Experimental Darexaban The serum concentration of Aminophylline can be decreased when it is combined with Darexaban. Investigational Darunavir The metabolism of Aminophylline can be decreased when combined with Darunavir. Approved Dasatinib The serum concentration of Aminophylline can be increased when it is combined with Dasatinib. Approved, Investigational Deferasirox The serum concentration of Aminophylline can be decreased when it is combined with Deferasirox. Approved, Investigational Delanzomib The serum concentration of Aminophylline can be decreased when it is combined with Delanzomib. Investigational Delapril The serum concentration of Aminophylline can be decreased when it is combined with Delapril. Experimental Delavirdine The metabolism of Aminophylline can be decreased when combined with Delavirdine. Approved Delorazepam The therapeutic efficacy of Delorazepam can be decreased when used in combination with Aminophylline. Approved, Illicit, Investigational Diazepam The therapeutic efficacy of Diazepam can be decreased when used in combination with Aminophylline. Approved, Illicit, Investigational, Vet Approved Dienestrol The serum concentration of Aminophylline can be increased when it is combined with Dienestrol. Approved, Investigational Diethylstilbestrol The serum concentration of Aminophylline can be increased when it is combined with Diethylstilbestrol. Approved, Investigational Dihydroergotamine The metabolism of Aminophylline can be decreased when combined with Dihydroergotamine. Approved, Investigational Diltiazem The metabolism of Aminophylline can be decreased when combined with Diltiazem. Approved, Investigational Disulfiram The serum concentration of Aminophylline can be increased when it is combined with Disulfiram. Approved Dosulepin The metabolism of Aminophylline can be decreased when combined with Dosulepin. Approved Doxefazepam The therapeutic efficacy of Doxefazepam can be decreased when used in combination with Aminophylline. Experimental Doxofylline The risk or severity of adverse effects can be increased when Aminophylline is combined with Doxofylline. Approved, Investigational Doxycycline The metabolism of Aminophylline can be decreased when combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The metabolism of Aminophylline can be decreased when combined with Dronedarone. Approved Ecabet The serum concentration of Aminophylline can be decreased when it is combined with Ecabet. Approved, Investigational Edoxaban The serum concentration of Aminophylline can be decreased when it is combined with Edoxaban. Approved Elafin The serum concentration of Aminophylline can be decreased when it is combined with Elafin. Investigational Enalapril The serum concentration of Aminophylline can be decreased when it is combined with Enalapril. Approved, Vet Approved Enalaprilat The serum concentration of Aminophylline can be decreased when it is combined with Enalaprilat. Approved Enalkiren The serum concentration of Aminophylline can be decreased when it is combined with Enalkiren. Experimental Enoxacin The metabolism of Aminophylline can be decreased when combined with Enoxacin. Approved, Investigational Enzalutamide The serum concentration of Aminophylline can be decreased when it is combined with Enzalutamide. Approved Epigallocatechin Gallate The serum concentration of Aminophylline can be decreased when it is combined with Epigallocatechin Gallate. Investigational Epimestrol The serum concentration of Aminophylline can be increased when it is combined with Epimestrol. Experimental Equol The serum concentration of Aminophylline can be increased when it is combined with Equol. Investigational Erythromycin The metabolism of Aminophylline can be decreased when combined with Erythromycin. Approved, Investigational, Vet Approved Esmolol Esmolol may decrease the bronchodilatory activities of Aminophylline. Approved Estazolam The therapeutic efficacy of Estazolam can be decreased when used in combination with Aminophylline. Approved, Illicit Estradiol The serum concentration of Aminophylline can be increased when it is combined with Estradiol. Approved, Investigational, Vet Approved Estradiol acetate The serum concentration of Aminophylline can be increased when it is combined with Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Aminophylline can be increased when it is combined with Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Aminophylline can be increased when it is combined with Estradiol valerate. Approved, Investigational, Vet Approved Estriol The serum concentration of Aminophylline can be increased when it is combined with Estriol. Approved, Investigational, Vet Approved Estrogens, esterified The serum concentration of Aminophylline can be increased when it is combined with Estrogens, esterified. Approved Estrone The serum concentration of Aminophylline can be increased when it is combined with Estrone. Approved Ethanol The serum concentration of Aminophylline can be increased when it is combined with Ethanol. Approved Ethinyl Estradiol The serum concentration of Aminophylline can be increased when it is combined with Ethinyl Estradiol. Approved Etizolam The therapeutic efficacy of Etizolam can be decreased when used in combination with Aminophylline. Approved Faldaprevir The serum concentration of Aminophylline can be decreased when it is combined with Faldaprevir. Investigational Febuxostat The serum concentration of the active metabolites of Aminophylline can be increased when Aminophylline is used in combination with Febuxostat. Approved Fleroxacin The serum concentration of Aminophylline can be increased when it is combined with Fleroxacin. Approved Fluconazole The metabolism of Aminophylline can be decreased when combined with Fluconazole. Approved, Investigational Fludiazepam The therapeutic efficacy of Fludiazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Flumazenil The therapeutic efficacy of Flumazenil can be decreased when used in combination with Aminophylline. Approved Flumequine The metabolism of Aminophylline can be decreased when combined with Flumequine. Withdrawn Flunitrazepam The therapeutic efficacy of Flunitrazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Flurazepam The therapeutic efficacy of Flurazepam can be decreased when used in combination with Aminophylline. Approved, Illicit, Investigational Fluvoxamine The metabolism of Aminophylline can be decreased when combined with Fluvoxamine. Approved, Investigational Formoterol The risk or severity of adverse effects can be increased when Aminophylline is combined with Formoterol. Approved, Investigational Fosamprenavir The metabolism of Aminophylline can be decreased when combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Aminophylline can be increased when it is combined with Fosaprepitant. Approved Fosinopril The serum concentration of Aminophylline can be decreased when it is combined with Fosinopril. Approved Fosphenytoin The serum concentration of Aminophylline can be decreased when it is combined with Fosphenytoin. Approved, Investigational Fusidic Acid The serum concentration of Aminophylline can be increased when it is combined with Fusidic Acid. Approved, Investigational Gabexate The serum concentration of Aminophylline can be decreased when it is combined with Gabexate. Investigational Garenoxacin The metabolism of Aminophylline can be decreased when combined with Garenoxacin. Investigational Gatifloxacin The metabolism of Aminophylline can be decreased when combined with Gatifloxacin. Approved, Investigational Geldanamycin The serum concentration of Aminophylline can be decreased when it is combined with Geldanamycin. Experimental, Investigational Gemifloxacin The metabolism of Aminophylline can be decreased when combined with Gemifloxacin. Approved, Investigational Genistein The serum concentration of Aminophylline can be increased when it is combined with Genistein. Investigational GM6001 The serum concentration of Aminophylline can be decreased when it is combined with GM6001. Experimental Grepafloxacin The metabolism of Aminophylline can be decreased when combined with Grepafloxacin. Approved, Investigational, Withdrawn Hexestrol The serum concentration of Aminophylline can be increased when it is combined with Hexestrol. Withdrawn Hexobarbital The serum concentration of Aminophylline can be decreased when it is combined with Hexobarbital. Approved Idelalisib The metabolism of Aminophylline can be decreased when combined with Idelalisib. Approved Idraparinux The serum concentration of Aminophylline can be decreased when it is combined with Idraparinux. Investigational Imatinib The metabolism of Aminophylline can be decreased when combined with Imatinib. Approved Imidapril The serum concentration of Aminophylline can be decreased when it is combined with Imidapril. Investigational Indacaterol The risk or severity of adverse effects can be increased when Aminophylline is combined with Indacaterol. Approved Indinavir The metabolism of Aminophylline can be decreased when combined with Indinavir. Approved Interferon Alfa-2a, Recombinant The metabolism of Aminophylline can be decreased when combined with Interferon Alfa-2a, Recombinant. Approved, Investigational Interferon Alfa-2b, Recombinant The metabolism of Aminophylline can be decreased when combined with Interferon Alfa-2b, Recombinant. Approved Interferon alfa-n1 The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n1. Approved, Investigational Interferon alfa-n3 The metabolism of Aminophylline can be decreased when combined with Interferon alfa-n3. Approved, Investigational Interferon alfacon-1 The metabolism of Aminophylline can be decreased when combined with Interferon alfacon-1. Approved, Investigational Interferon beta-1a The metabolism of Aminophylline can be decreased when combined with Interferon beta-1a. Approved, Investigational Interferon beta-1b The metabolism of Aminophylline can be decreased when combined with Interferon beta-1b. Approved Interferon gamma-1b The metabolism of Aminophylline can be decreased when combined with Interferon gamma-1b. Approved, Investigational Isavuconazole The serum concentration of Aminophylline can be increased when it is combined with Isavuconazole. Approved, Investigational Isavuconazonium The metabolism of Aminophylline can be decreased when combined with Isavuconazonium. Approved, Investigational Isoflurophate The serum concentration of Aminophylline can be decreased when it is combined with Isoflurophate. Approved, Investigational, Withdrawn Isoniazid The serum concentration of Aminophylline can be increased when it is combined with Isoniazid. Approved, Investigational Isoprenaline The serum concentration of Aminophylline can be decreased when it is combined with Isoprenaline. Approved, Investigational Isradipine The metabolism of Aminophylline can be decreased when combined with Isradipine. Approved, Investigational Itraconazole The metabolism of Aminophylline can be decreased when combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Aminophylline can be increased when it is combined with Ivacaftor. Approved Ixazomib The serum concentration of Aminophylline can be decreased when it is combined with Ixazomib. Approved, Investigational Josamycin The metabolism of Aminophylline can be decreased when combined with Josamycin. Approved, Investigational Ketoconazole The metabolism of Aminophylline can be decreased when combined with Ketoconazole. Approved, Investigational Kitasamycin The metabolism of Aminophylline can be decreased when combined with Kitasamycin. Experimental Lepirudin The serum concentration of Aminophylline can be decreased when it is combined with Lepirudin. Approved Letaxaban The serum concentration of Aminophylline can be decreased when it is combined with Letaxaban. Investigational Levofloxacin The metabolism of Aminophylline can be decreased when combined with Levofloxacin. Approved, Investigational Levothyroxine The metabolism of Aminophylline can be increased when combined with Levothyroxine. Approved Lidocaine The metabolism of Aminophylline can be decreased when combined with Lidocaine. Approved, Vet Approved Linagliptin The serum concentration of Aminophylline can be decreased when it is combined with Linagliptin. Approved Liothyronine The metabolism of Aminophylline can be increased when combined with Liothyronine. Approved, Vet Approved Liotrix The metabolism of Aminophylline can be increased when combined with Liotrix. Approved Lisinopril The serum concentration of Aminophylline can be decreased when it is combined with Lisinopril. Approved, Investigational Lithium The serum concentration of Lithium can be decreased when it is combined with Aminophylline. Approved Lobeglitazone The metabolism of Aminophylline can be decreased when combined with Lobeglitazone. Approved, Investigational Lopinavir The metabolism of Aminophylline can be decreased when combined with Lopinavir. Approved Lorazepam The therapeutic efficacy of Lorazepam can be decreased when used in combination with Aminophylline. Approved Lormetazepam The therapeutic efficacy of Lormetazepam can be decreased when used in combination with Aminophylline. Approved Lorpiprazole The serum concentration of Aminophylline can be increased when it is combined with Lorpiprazole. Approved Lovastatin The metabolism of Aminophylline can be decreased when combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Aminophylline can be increased when it is combined with Luliconazole. Approved Lumacaftor The metabolism of Aminophylline can be increased when combined with Lumacaftor. Approved Medazepam The therapeutic efficacy of Medazepam can be decreased when used in combination with Aminophylline. Experimental Melagatran The serum concentration of Aminophylline can be decreased when it is combined with Melagatran. Experimental Mepindolol Mepindolol may decrease the bronchodilatory activities of Aminophylline. Experimental Mestranol The serum concentration of Aminophylline can be increased when it is combined with Mestranol. Approved Methallenestril The serum concentration of Aminophylline can be increased when it is combined with Methallenestril. Experimental Methimazole The serum concentration of Aminophylline can be increased when it is combined with Methimazole. Approved Methohexital The serum concentration of Aminophylline can be decreased when it is combined with Methohexital. Approved Methotrexate The serum concentration of Aminophylline can be increased when it is combined with Methotrexate. Approved Methylphenobarbital The serum concentration of Aminophylline can be decreased when it is combined with Methylphenobarbital. Approved Methylthiouracil The serum concentration of Aminophylline can be increased when it is combined with Methylthiouracil. Experimental Metoprolol Metoprolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Mexiletine The metabolism of Aminophylline can be decreased when combined with Mexiletine. Approved, Investigational Midazolam The therapeutic efficacy of Midazolam can be decreased when used in combination with Aminophylline. Approved, Illicit Midostaurin The metabolism of Aminophylline can be decreased when combined with Midostaurin. Approved, Investigational Mifepristone The serum concentration of Aminophylline can be increased when it is combined with Mifepristone. Approved, Investigational Mitotane The serum concentration of Aminophylline can be decreased when it is combined with Mitotane. Approved Moexipril The serum concentration of Aminophylline can be decreased when it is combined with Moexipril. Approved Moxestrol The serum concentration of Aminophylline can be increased when it is combined with Moxestrol. Experimental N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline The serum concentration of Aminophylline can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline. Experimental Nafamostat The serum concentration of Aminophylline can be decreased when it is combined with Nafamostat. Approved, Investigational Nalidixic Acid The metabolism of Aminophylline can be decreased when combined with Nalidixic Acid. Approved, Investigational Natural alpha interferon The metabolism of Aminophylline can be decreased when combined with Natural alpha interferon. Approved, Investigational Nebivolol Nebivolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Nefazodone The metabolism of Aminophylline can be decreased when combined with Nefazodone. Approved, Withdrawn Nelfinavir The metabolism of Aminophylline can be decreased when combined with Nelfinavir. Approved Nemonoxacin The metabolism of Aminophylline can be decreased when combined with Nemonoxacin. Investigational Netazepide The therapeutic efficacy of Netazepide can be decreased when used in combination with Aminophylline. Investigational Netupitant The serum concentration of Aminophylline can be increased when it is combined with Netupitant. Approved, Investigational Nevirapine The metabolism of Aminophylline can be increased when combined with Nevirapine. Approved Nicotine The metabolism of Aminophylline can be decreased when combined with Nicotine. Approved Nilotinib The metabolism of Aminophylline can be decreased when combined with Nilotinib. Approved, Investigational Nitrazepam The therapeutic efficacy of Nitrazepam can be decreased when used in combination with Aminophylline. Approved Nitroaspirin The serum concentration of Aminophylline can be decreased when it is combined with Nitroaspirin. Investigational Norfloxacin The metabolism of Aminophylline can be decreased when combined with Norfloxacin. Approved Olaparib The metabolism of Aminophylline can be decreased when combined with Olaparib. Approved Oleandomycin The metabolism of Aminophylline can be decreased when combined with Oleandomycin. Vet Approved Olodaterol The risk or severity of adverse effects can be increased when Aminophylline is combined with Olodaterol. Approved Omapatrilat The serum concentration of Aminophylline can be decreased when it is combined with Omapatrilat. Investigational Osimertinib The serum concentration of Aminophylline can be increased when it is combined with Osimertinib. Approved Otamixaban The serum concentration of Aminophylline can be decreased when it is combined with Otamixaban. Investigational Oxazepam The therapeutic efficacy of Oxazepam can be decreased when used in combination with Aminophylline. Approved Oxolinic acid The metabolism of Aminophylline can be decreased when combined with Oxolinic acid. Experimental Oxprenolol Oxprenolol may decrease the bronchodilatory activities of Aminophylline. Approved Palbociclib The serum concentration of Aminophylline can be increased when it is combined with Palbociclib. Approved, Investigational Pancuronium The risk or severity of adverse effects can be increased when Aminophylline is combined with Pancuronium. Approved Pazufloxacin The metabolism of Aminophylline can be decreased when combined with Pazufloxacin. Investigational Pefloxacin The metabolism of Aminophylline can be decreased when combined with Pefloxacin. Approved Peginterferon alfa-2a The metabolism of Aminophylline can be decreased when combined with Peginterferon alfa-2a. Approved, Investigational Peginterferon alfa-2b The serum concentration of Aminophylline can be increased when it is combined with Peginterferon alfa-2b. Approved Peginterferon beta-1a The metabolism of Aminophylline can be decreased when combined with Peginterferon beta-1a. Approved Penbutolol Penbutolol may decrease the bronchodilatory activities of Aminophylline. Approved, Investigational Pentobarbital The metabolism of Aminophylline can be increased when combined with Pentobarbital. Approved, Investigational, Vet Approved Pentoxifylline The serum concentration of Aminophylline can be increased when it is combined with Pentoxifylline. Approved, Investigational Perindopril The serum concentration of Aminophylline can be decreased when it is combined with Perindopril. Approved PF-477736 The therapeutic efficacy of PF-477736 can be decreased when used in combination with Aminophylline. Investigational Phenobarbital The metabolism of Aminophylline can be increased when combined with Phenobarbital. Approved, Investigational Phenytoin The serum concentration of Aminophylline can be decreased when it is combined with Phenytoin. Approved, Vet Approved Phosphoramidon The serum concentration of Aminophylline can be decreased when it is combined with Phosphoramidon. Experimental Pipemidic acid The metabolism of Aminophylline can be decreased when combined with Pipemidic acid. Experimental Pirenzepine The therapeutic efficacy of Pirenzepine can be decreased when used in combination with Aminophylline. Approved Piromidic acid The metabolism of Aminophylline can be decreased when combined with Piromidic acid. Experimental Pitolisant The serum concentration of Aminophylline can be decreased when it is combined with Pitolisant. Approved, Investigational Polyestradiol phosphate The serum concentration of Aminophylline can be increased when it is combined with Polyestradiol phosphate. Approved Posaconazole The metabolism of Aminophylline can be decreased when combined with Posaconazole. Approved, Investigational, Vet Approved Potassium Iodide The serum concentration of Aminophylline can be increased when it is combined with Potassium Iodide. Approved Prazepam The therapeutic efficacy of Prazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Primidone The metabolism of Aminophylline can be increased when combined with Primidone. Approved, Vet Approved Prinomastat The serum concentration of Aminophylline can be decreased when it is combined with Prinomastat. Investigational Probenecid The serum concentration of Aminophylline can be increased when it is combined with Probenecid. Approved, Investigational Promestriene The serum concentration of Aminophylline can be increased when it is combined with Promestriene. Investigational Propafenone The serum concentration of Aminophylline can be increased when it is combined with Propafenone. Approved Propylthiouracil The serum concentration of Aminophylline can be increased when it is combined with Propylthiouracil. Approved, Investigational Prulifloxacin The metabolism of Aminophylline can be decreased when combined with Prulifloxacin. Investigational Quazepam The therapeutic efficacy of Quazepam can be decreased when used in combination with Aminophylline. Approved, Illicit Quinapril The serum concentration of Aminophylline can be decreased when it is combined with Quinapril. Approved, Investigational Quinestrol The serum concentration of Aminophylline can be increased when it is combined with Quinestrol. Approved Quinine The serum concentration of Aminophylline can be increased when it is combined with Quinine. Approved Racecadotril The serum concentration of Aminophylline can be decreased when it is combined with Racecadotril. Investigational Ramipril The serum concentration of Aminophylline can be decreased when it is combined with Ramipril. Approved Ranolazine The metabolism of Aminophylline can be decreased when combined with Ranolazine. Approved, Investigational Regadenoson Aminophylline may decrease the vasodilatory activities of Regadenoson. Approved, Investigational Remikiren The serum concentration of Aminophylline can be decreased when it is combined with Remikiren. Approved Rifabutin The metabolism of Aminophylline can be increased when combined with Rifabutin. Approved, Investigational Rifampicin The metabolism of Aminophylline can be increased when combined with Rifampicin. Approved Rifapentine The metabolism of Aminophylline can be increased when combined with Rifapentine. Approved, Investigational Riociguat Aminophylline may increase the hypotensive activities of Riociguat. Approved Ritonavir The serum concentration of Aminophylline can be decreased when it is combined with Ritonavir. Approved, Investigational Rivaroxaban The serum concentration of Aminophylline can be decreased when it is combined with Rivaroxaban. Approved Ropinirole The metabolism of Aminophylline can be decreased when combined with Ropinirole. Approved, Investigational Rosoxacin The metabolism of Aminophylline can be decreased when combined with Rosoxacin. Approved, Investigational Rucaparib The metabolism of Aminophylline can be decreased when combined with Rucaparib. Approved, Investigational Rufloxacin The metabolism of Aminophylline can be decreased when combined with Rufloxacin. Experimental S-3304 The serum concentration of Aminophylline can be decreased when it is combined with S-3304. Investigational Saquinavir The metabolism of Aminophylline can be decreased when combined with Saquinavir. Approved, Investigational Sarilumab The therapeutic efficacy of Aminophylline can be decreased when used in combination with Sarilumab. Approved, Investigational Saxagliptin The serum concentration of Aminophylline can be decreased when it is combined with Saxagliptin. Approved Secobarbital The serum concentration of Aminophylline can be decreased when it is combined with Secobarbital. Approved, Vet Approved Secoisolariciresinol The serum concentration of Aminophylline can be increased when it is combined with Secoisolariciresinol. Investigational Sildenafil The metabolism of Aminophylline can be decreased when combined with Sildenafil. Approved, Investigational Siltuximab The serum concentration of Aminophylline can be decreased when it is combined with Siltuximab. Approved, Investigational Simeprevir The serum concentration of Aminophylline can be increased when it is combined with Simeprevir. Approved Sitafloxacin The metabolism of Aminophylline can be decreased when combined with Sitafloxacin. Experimental, Investigational Sitagliptin The serum concentration of Aminophylline can be decreased when it is combined with Sitagliptin. Approved, Investigational Sivelestat The serum concentration of Aminophylline can be decreased when it is combined with Sivelestat. Investigational SJG-136 The therapeutic efficacy of SJG-136 can be decreased when used in combination with Aminophylline. Investigational Solithromycin The metabolism of Aminophylline can be decreased when combined with Solithromycin. Investigational Sparfloxacin The metabolism of Aminophylline can be decreased when combined with Sparfloxacin. Approved, Investigational Spirapril The serum concentration of Aminophylline can be decreased when it is combined with Spirapril. Approved St. John's Wort The serum concentration of Aminophylline can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stiripentol The serum concentration of Aminophylline can be increased when it is combined with Stiripentol. Approved Sulfisoxazole The metabolism of Aminophylline can be decreased when combined with Sulfisoxazole. Approved, Vet Approved Synthetic Conjugated Estrogens, A The serum concentration of Aminophylline can be increased when it is combined with Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B The serum concentration of Aminophylline can be increased when it is combined with Synthetic Conjugated Estrogens, B. Approved Telaprevir The metabolism of Aminophylline can be decreased when combined with Telaprevir. Approved, Withdrawn Telithromycin The metabolism of Aminophylline can be decreased when combined with Telithromycin. Approved Temafloxacin The metabolism of Aminophylline can be decreased when combined with Temafloxacin. Withdrawn Temazepam The therapeutic efficacy of Temazepam can be decreased when used in combination with Aminophylline. Approved, Investigational Temocapril The serum concentration of Aminophylline can be decreased when it is combined with Temocapril. Experimental, Investigational Tenofovir disoproxil The metabolism of Aminophylline can be decreased when combined with Tenofovir disoproxil. Approved, Investigational Teriflunomide The serum concentration of Aminophylline can be decreased when it is combined with Teriflunomide. Approved Tertatolol Tertatolol may decrease the bronchodilatory activities of Aminophylline. Experimental Theophylline The metabolism of Aminophylline can be decreased when combined with Theophylline. Approved Thiabendazole The metabolism of Aminophylline can be decreased when combined with Thiabendazole. Approved, Vet Approved Thiamylal The serum concentration of Aminophylline can be decreased when it is combined with Thiamylal. Approved, Vet Approved Thiopental The therapeutic efficacy of Thiopental can be decreased when used in combination with Aminophylline. Approved, Vet Approved Thiorphan The serum concentration of Aminophylline can be decreased when it is combined with Thiorphan. Experimental Thyroid, porcine The metabolism of Aminophylline can be increased when combined with Thyroid, porcine. Approved Tibolone The serum concentration of Aminophylline can be increased when it is combined with Tibolone. Approved, Investigational Ticlopidine The metabolism of Aminophylline can be decreased when combined with Ticlopidine. Approved Tipranavir The serum concentration of Aminophylline can be decreased when it is combined with Tipranavir. Approved, Investigational Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Aminophylline. Approved, Investigational Tocilizumab The serum concentration of Aminophylline can be decreased when it is combined with Tocilizumab. Approved Trandolapril The serum concentration of Aminophylline can be decreased when it is combined with Trandolapril. Approved Triazolam The therapeutic efficacy of Triazolam can be decreased when used in combination with Aminophylline. Approved, Investigational Trovafloxacin The metabolism of Aminophylline can be decreased when combined with Trovafloxacin. Approved, Investigational, Withdrawn Tylosin The metabolism of Aminophylline can be decreased when combined with Tylosin. Vet Approved Ubenimex The serum concentration of Aminophylline can be decreased when it is combined with Ubenimex. Experimental, Investigational Ulinastatin The serum concentration of Aminophylline can be decreased when it is combined with Ulinastatin. Investigational Vemurafenib The serum concentration of Aminophylline can be increased when it is combined with Vemurafenib. Approved Venlafaxine The metabolism of Aminophylline can be decreased when combined with Venlafaxine. Approved Verapamil The metabolism of Aminophylline can be decreased when combined with Verapamil. Approved Vildagliptin The serum concentration of Aminophylline can be decreased when it is combined with Vildagliptin. Approved, Investigational Voriconazole The metabolism of Aminophylline can be decreased when combined with Voriconazole. Approved, Investigational Ximelagatran The serum concentration of Aminophylline can be decreased when it is combined with Ximelagatran. Approved, Investigational, Withdrawn Z-Val-Ala-Asp fluoromethyl ketone The serum concentration of Aminophylline can be decreased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone. Experimental Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Aminophylline. Approved, Investigational Zeranol The serum concentration of Aminophylline can be increased when it is combined with Zeranol. Vet Approved Ziprasidone The metabolism of Aminophylline can be decreased when combined with Ziprasidone. Approved Zofenopril The serum concentration of Aminophylline can be decreased when it is combined with Zofenopril. Experimental Zucapsaicin The metabolism of Aminophylline can be decreased when combined with Zucapsaicin. Approved, Investigational - Food Interactions
- Limit caffeine intake.
- Take with food.
- Vitamin B6 needs increased, supplement recommended.
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015354
- KEGG Drug
- D00227
- PubChem Compound
- 9433
- PubChem Substance
- 46508784
- ChemSpider
- 9062
- ChEBI
- 2659
- ChEMBL
- CHEMBL1370561
- Therapeutic Targets Database
- DAP000613
- PharmGKB
- PA164781029
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Aminophylline
- ATC Codes
- R03DA20 — Combinations of xanthines
- R03DA — Xanthines
- R03D — OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- R03DA — Xanthines
- R03D — OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- R03DB — Xanthines and adrenergics
- R03D — OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- AHFS Codes
- 86:16.00 — Respiratory Smooth Muscle Relaxants
- MSDS
- Download (72.7 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Amend
- C.O. Truxton Inc.
- Cardinal Health
- Carlisle Laboratories Inc.
- Dispensing Solutions
- G & W Labs
- General Injectables and Vaccines Inc.
- Hospira Inc.
- Kaiser Foundation Hospital
- Lake Erie Medical and Surgical Supply
- Major Pharmaceuticals
- Murfreesboro Pharmaceutical Nursing Supply
- PCA LLC
- Pharmedix
- Prescript Pharmaceuticals
- West-Ward Pharmaceuticals
- Dosage forms
Form Route Strength Injection, solution Intravenous 25 mg/mL Tablet Oral 100 mg/1 Tablet Oral 200 mg/1 Solution Intravenous 50 mg Solution Intravenous 25 mg Tablet Oral 100 mg Tablet Oral 97.5 mg Tablet, extended release Oral 225 mg Tablet, extended release Oral 350 mg - Prices
Unit description Cost Unit Aminophylline 250 mg/10 ml vial 0.48USD ml Aminophylline 25 mg/ml 0.41USD ml Phyllocontin-350 350 mg Sustained-Release Tablet 0.31USD tablet Aminophylline 100 mg tablet 0.26USD tablet Phyllocontin 225 mg Sustained-Release Tablet 0.24USD tablet Aminophylline powder 0.17USD g Aminophylline 200 mg tablet 0.15USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility 2E+005 mg/L MERCK INDEX (1996) logP -3.03 Not Available - Predicted Properties
Property Value Source logP -0.77 ChemAxon pKa (Strongest Acidic) 7.82 ChemAxon pKa (Strongest Basic) -0.78 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 3 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 69.3 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 44.93 m3·mol-1 ChemAxon Polarizability 16.86 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9778 Blood Brain Barrier + 0.5908 Caco-2 permeable - 0.6802 P-glycoprotein substrate Substrate 0.7341 P-glycoprotein inhibitor I Non-inhibitor 0.9164 P-glycoprotein inhibitor II Non-inhibitor 0.9673 Renal organic cation transporter Non-inhibitor 0.7935 CYP450 2C9 substrate Non-substrate 0.8073 CYP450 2D6 substrate Non-substrate 0.8093 CYP450 3A4 substrate Substrate 0.5482 CYP450 1A2 substrate Non-inhibitor 0.8726 CYP450 2C9 inhibitor Non-inhibitor 0.9332 CYP450 2D6 inhibitor Non-inhibitor 0.9633 CYP450 2C19 inhibitor Non-inhibitor 0.9184 CYP450 3A4 inhibitor Non-inhibitor 0.8031 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8858 Ames test Non AMES toxic 0.6724 Carcinogenicity Non-carcinogens 0.8696 Biodegradation Not ready biodegradable 0.9149 Rat acute toxicity 2.4979 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7876 hERG inhibition (predictor II) Inhibitor 0.6143
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-001i-1900000000-f6d60952fa154f363515
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as monoalkylamines. These are organic compounds containing an primary aliphatic amine group.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Amines
- Direct Parent
- Monoalkylamines
- Alternative Parents
- Organopnictogen compounds / Hydrocarbon derivatives
- Substituents
- Organopnictogen compound / Hydrocarbon derivative / Primary aliphatic amine / Aromatic heteropolycyclic compound
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
- Gene Name
- PDE3A
- Uniprot ID
- Q14432
- Uniprot Name
- cGMP-inhibited 3',5'-cyclic phosphodiesterase A
- Molecular Weight
- 124978.06 Da
References
- Hirota K, Yoshioka H, Kabara S, Koizumi Y, Abe H, Sato T, Matsuki A: Spasmolytic effects of colforsin daropate on serotonin-induced pulmonary hypertension and bronchoconstriction in dogs. Acta Anaesthesiol Scand. 2002 Mar;46(3):297-302. [PubMed:11939921]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Purine nucleoside binding
- Specific Function
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- ADORA1
- Uniprot ID
- P30542
- Uniprot Name
- Adenosine receptor A1
- Molecular Weight
- 36511.325 Da
References
- Yamamoto S, Nakanishi O, Matsui T, Shinohara N, Kinoshita H, Lambert C, Ishikawa T: Intrathecal adenosine A1 receptor agonist attenuates hyperalgesia without inhibiting spinal glutamate release in the rat. Cell Mol Neurobiol. 2003 Apr;23(2):175-85. [PubMed:12735630]
- Lerman BB: Response of nonreentrant catecholamine-mediated ventricular tachycardia to endogenous adenosine and acetylcholine. Evidence for myocardial receptor-mediated effects. Circulation. 1993 Feb;87(2):382-90. [PubMed:8425287]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- G-protein coupled adenosine receptor activity
- Specific Function
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase. Possible role in reproduction.
- Gene Name
- ADORA3
- Uniprot ID
- P0DMS8
- Uniprot Name
- Adenosine receptor A3
- Molecular Weight
- 36184.175 Da
References
- Stella L, de Novellis V, Marabese I, Berrino L, Maione S, Filippelli A, Rossi F: The role of A3 adenosine receptors in central regulation of arterial blood pressure. Br J Pharmacol. 1998 Oct;125(3):437-40. [PubMed:9806324]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Activator
- General Function
- Transcription factor binding
- Specific Function
- Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an impo...
- Gene Name
- HDAC2
- Uniprot ID
- Q92769
- Uniprot Name
- Histone deacetylase 2
- Molecular Weight
- 55363.855 Da
References
- Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ: A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8921-6. Epub 2002 Jun 17. [PubMed:12070353]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Steroid hydroxylase activity
- Specific Function
- Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
- Gene Name
- CYP2E1
- Uniprot ID
- P05181
- Uniprot Name
- Cytochrome P450 2E1
- Molecular Weight
- 56848.42 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:08